On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

The completion of this study could positively impact Pfizer and BioNTech’s stock performance, as successful results may lead to new vaccine offerings, enhancing their market position. This development ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...